다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Pharmacological reports : Pr, v.67 no.2, 2015년, pp.195 - 203
Kumar, Anil , Singh, Arti , Ekavali,
AI-Helper
Alzheimer's disease acknowledged as progressive multifarious neurodegenerative disorder, is the leading cause of dementia in late adult life. Pathologically it is characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques. ...
Neuropharmacology Anand 76 27 2014 10.1016/j.neuropharm.2013.07.004 Therapeutics of Alzheimer's disease: past, present and future
Alzheimers Dement Alzheimer's Association 10 2 47 2014 10.1016/j.jalz.2014.02.001 Alzheimer's disease facts and figures
Arch Med Res Ramirez-Bermudez 43 8 595 2012 10.1016/j.arcmed.2012.11.008 Alzheimer's disease: critical notes on the history of a medical concept
Prog Neurobiol Auld 68 3 209 2002 10.1016/S0301-0082(02)00079-5 Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies
Dement Geriatr Cogn Disord Farlow 25 5 408 2008 10.1159/000122962 Treatment options in Alzheimer's disease: maximizing benefit, managing expectations
Prog Neuropsychopharmacol Biol Psychiatry Kurz 35 2 373 2011 10.1016/j.pnpbp.2010.07.018 Novel insights for the treatment of Alzheimer's disease
Drugs Future Kumar 33 5 433 2008 10.1358/dof.2008.033.05.1192677 Neuropathology and therapeutic management of Alzheimer's disease - an update
J Neurochem Hardy 110 4 1129 2009 10.1111/j.1471-4159.2009.06181.x The amyloid hypothesis for Alzheimer's disease: a critical reappraisal
Neuroscientist Dal Prà 2014 Do astrocytes collaborate with neurons in spreading the “infectious” Aβ and tau drivers of Alzheimer's disease?
Br J Clin Pharmacol Salomone 73 4 504 2012 10.1111/j.1365-2125.2011.04134.x New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs
Curr Alzheimer Res Rosenmann 10 3 217 2013 10.2174/1567205011310030001 Immunotherapy for targeting tau pathology in Alzheimers disease and tauopathies
Neuroscientist Antanitus 4 3 154 1998 10.1177/107385849800400310 A theory of cortical neuron-astrocyte interaction
Biol Res Roth 38 4 381 2005 10.4067/S0716-97602005000400011 Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation
J Neurol Sci Galimberti 333 1 50 2013 10.1016/j.jns.2012.12.013 Immunotherapy against amyloid pathology in Alzheimer's disease
J Neurochem Subasinghe 84 3 471 2003 10.1046/j.1471-4159.2003.01552.x Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes
Prog Neurobiol Xu 97 1 1 2012 10.1016/j.pneurobio.2012.02.002 Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease
Int J Mol Med Armato 31 1 3 2013 10.3892/ijmm.2012.1162 Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia
Brain Res Yasojima 919 1 115 2001 10.1016/S0006-8993(01)03008-6 Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain
Acta Neuropathol Braak 121 5 589 2011 10.1007/s00401-011-0825-z Alzheimer's pathogenesis: is there neuron-to-neuron propagation?
Int J Biochem Cell Biol Tuppo 37 2 289 2005 10.1016/j.biocel.2004.07.009 The role of inflammation in Alzheimer's disease
Science Eisele 330 6006 980 2010 10.1126/science.1194516 Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis
Proc Natl Acad Sci U S A Talantova 110 27 2518 2013 10.1073/pnas.1306832110 Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss
Mech Ageing Dev Silvestrelli 127 2 148 2006 10.1016/j.mad.2005.09.018 Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology
Nature Schenk 400 6740 173 1999 10.1038/22124 Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
J Neurochem Zlokovic 89 4 807 2004 10.1111/j.1471-4159.2004.02385.x Clearing amyloid through the blood-brain barrier
Nat Med Sagare 13 9 1029 2007 10.1038/nm1635 Clearance of amyloid-β by circulating lipoprotein receptors
J Alzheimers Dis Yan 16 4 833 2009 10.3233/JAD-2009-1030 RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation?
J Neurochem Ghosh 120 1 71 2012 10.1111/j.1471-4159.2011.07476.x Developing β-secretase inhibitors for treatment of Alzheimer's disease
FASEB J Chang 25 2 775 2011 10.1096/fj.10-167213 β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice
Arch Med Sci Aisen 7 1 102 2011 10.5114/aoms.2011.20612 Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Al phase Study)
Alzheimers Dement DaSilva 5 4 425 2009 10.1016/j.jalz.2009.04.950 Scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease
Curr Alzheimer Res Janusz 7 4 323 2010 10.2174/156720510791162377 Colostral proline-rich polypeptides - immunoregulatory properties and prospects of therapeutic use in Alzheimers disease
Proc Natl Acad Sci U S A Jacobsen 105 25 8754 2008 10.1073/pnas.0710823105 Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
Nat Med Saito 11 4 434 2005 10.1038/nm1206 Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
J Alzheimers Dis Scarpini 26 2 211 2011 10.3233/JAD-2011-110134 Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial
Neurodegener Dis Hock 2 5 273 2006 10.1159/000090368 Clinical observations with AN-1792 using TAPIR analyses
Nat Med Nicoll 9 4 448 2003 10.1038/nm840 Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Brain Res Rev Buée 33 1 95 2000 10.1016/S0165-0173(00)00019-9 Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
J Neurochem Engel 99 6 1445 2006 10.1111/j.1471-4159.2006.04139.x Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert
Proc Natl Acad Sci U S A Zhang 102 1 227 2005 10.1073/pnas.0406361102 Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model
J Neurosci Brunden 30 41 13861 2010 10.1523/JNEUROSCI.3059-10.2010 Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy
Curr Pharm Des Gozes 17 10 1040 2011 10.2174/138161211795589373 NAP (davunetide) provides functional and structural neuroprotection
FASEB J Atamna 22 3 703 2008 10.1096/fj.07-9610com Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways
J Alzheimers Dis Rojo 19 2 573 2010 10.3233/JAD-2010-1262 Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease
Autophagy Congdon 8 4 609 2012 10.4161/auto.19048 Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo
Br J Pharmacol Pfaffendorf 122 1 95 1997 10.1038/sj.bjp.0701355 The interaction between methylene blue and the cholinergic system
Cell Mol Life Sci Giommarelli 67 6 995 2010 10.1007/s00018-009-0233-x The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
J Biol Chem Ma 288 6 4056 2013 10.1074/jbc.M112.393751 Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice
J Biol Chem Chai 286 39 34457 2011 10.1074/jbc.M111.229633 Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression
J Neurosci Puzzo 29 25 8075 2009 10.1523/JNEUROSCI.0864-09.2009 Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model
Psychopharmacology (Berl) Cheng 212 2 181 2010 10.1007/s00213-010-1943-3 Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats
Biochem Biophys Res Commun Park 408 4 602 2011 10.1016/j.bbrc.2011.04.068 Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation
J Alzheimers Dis Froestl 33 3 547 2013 10.3233/JAD-2012-121537 Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes
J Neural Transm Schaeffer 118 9 1273 2011 10.1007/s00702-011-0619-4 Inhibition of phospholipase A2 in rat brain decreases the levels of total tau protein
J Neurosci Oliveira 30 49 16419 2010 10.1523/JNEUROSCI.3317-10.2010 Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits
JAMA Watkins 271 13 992 1994 10.1001/jama.1994.03510370044030 Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
J Mol Neurosci Maelicke 40 1-2 135 2010 10.1007/s12031-009-9269-5 Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy
Cell Mol Neurobiol Zhang 28 2 173 2008 10.1007/s10571-007-9163-z Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase
J Neurochem Fisher 120 1 22 2012 10.1111/j.1471-4159.2011.07507.x Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease
Expert Opin Ther Pat Collina 23 5 597 2013 10.1517/13543776.2013.769522 Sigma receptor modulators: a patent review
CNS Neurosci Ther Echeverria 18 7 517 2012 10.1111/j.1755-5949.2012.00317.x Cotinine: a potential new therapeutic agent against Alzheimer's disease
J Neurochem Rissman 103 4 1285 2007 10.1111/j.1471-4159.2007.04832.x GABAA receptors in aging and Alzheimer's disease
Future Med Chem Limon 3 2 149 2011 10.4155/fmc.10.291 GABAergic drugs and Alzheimer's disease
J Neurochem Marcade 106 1 392 2008 10.1111/j.1471-4159.2008.05396.x Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing
CNS Drugs Butterfield 17 9 641 2003 10.2165/00023210-200317090-00004 The glutamatergic system and Alzheimer's disease
Eur J Pharmacol Miguel-Hidalgo 692 1 38 2012 10.1016/j.ejphar.2012.07.032 Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β 1-40
Int J Geriatr Psychiatry Hellweg 27 6 651 2012 10.1002/gps.2766 Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD
J Alzheimers Dis Ni 33 3 841 2013 10.3233/JAD-2012-121447 Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain
Prog Neurobiol Rodriguez 99 1 15 2012 10.1016/j.pneurobio.2012.06.010 The serotonergic system in ageing and Alzheimer's disease
Trends Pharmacol Sci King 29 9 482 2008 10.1016/j.tips.2008.07.001 A role for the 5-HT 1A, 5-HT 4 and 5-HT 6 receptors in learning and memory
Br J Clin Pharmacol Patat 67 3 299 2009 10.1111/j.1365-2125.2008.03348.x Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects
Int J Geriatr Psychiatry Maher-Edwards 26 5 536 2011 10.1002/gps.2562 SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Behav Pharmacol Gravius 22 2 122 2011 10.1097/FBP.0b013e328343d804 Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity
J Pharmacol Exp Ther Motawaj 336 2 479 2011 10.1124/jpet.110.174458 Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease
Drug News Perspect Chazot 23 2 99 2010 10.1358/dnp.2010.23.2.1475899 Therapeutic potential of histamine H3 receptor antagonists in dementias
J Pharmacol Exp Ther Brioni 336 1 38 2011 10.1124/jpet.110.166876 Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease
Br J Clin Pharmacol Othman 75 5 1299 2013 10.1111/j.1365-2125.2012.04472.x Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers
Curr Alzheimer Res Nathan 10 3 240 2013 10.2174/1567205011310030003 The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimers disease: a preliminary investigation
Exp Neurol Dall’Igna 203 1 241 2007 10.1016/j.expneurol.2006.08.008 Caffeine and adenosine A 2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice
Neuropathol Appl Neurobiol Cottrell 28 5 390 2002 10.1046/j.1365-2990.2002.00414.x The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease
J Neurol Sci Baloyannis 283 1 153 2009 10.1016/j.jns.2009.02.370 Dendritic pathology in Alzheimer's disease
Adv Drug Deliv Rev Lee 61 14 1316 2009 10.1016/j.addr.2009.07.016 The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?
J Neural Transm Suppl Gutzmann 54 301 1998 10.1007/978-3-7091-7508-8_30 Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study
J Biol Chem Wen 286 18 16504 2011 10.1074/jbc.M110.208447 Alternative mitochondrial electron transfer as a novel strategy for neuroprotection
Arch Neurol Galasko 69 7 836 2012 10.1001/archneurol.2012.85 Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
J Alzheimers Dis Manczak 20 609 2010 10.3233/JAD-2010-100564 Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Cochrane Database Syst Rev Farina 11 2012 Vitamin E for Alzheimer's dementia and mild cognitive impairment
Alzheimers Dement Dysken 10 1 36 2014 10.1016/j.jalz.2013.01.014 Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data
Neuroscience Javed 210 340 2012 10.1016/j.neuroscience.2012.02.046 Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type
Curr Neuropharmacol Cardinali 8 3 218 2010 10.2174/157015910792246209 Clinical aspects of melatonin intervention in Alzheimer's disease progression
J Neurosci Nicolakakis 28 37 9287 2008 10.1523/JNEUROSCI.3348-08.2008 Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist
J Alzheimers Dis Lichtenstein 22 4 1135 2010 10.3233/JAD-2010-101332 Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives
J Neurochem Choi 124 1 59 2013 10.1111/jnc.12059 Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease
Ann Neurol Li 60 6 729 2006 10.1002/ana.21053 Simvastatin enhances learning and memory independent of amyloid load in mice
J Neurochem Bösel 92 6 1386 2005 10.1111/j.1471-4159.2004.02980.x Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones
Exp Neurol Fonseca 223 2 282 2010 10.1016/j.expneurol.2009.09.013 Cholesterol and statins in Alzheimer's disease: current controversies
Antioxid Redox Signal Barron 8 11-12 2047 2006 10.1089/ars.2006.8.2047 Reproductive hormones modulate oxidative stress in Alzheimer's disease
Acta Pharmacol Sin Yue 28 8 1129 2007 10.1111/j.1745-7254.2007.00618.x Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes
Arch Neurol Lu 63 2 177 2006 10.1001/archneur.63.2.nct50002 Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
Curr Alzheimer Res Carroll 9 1 18 2012 10.2174/156720512799015109 The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease
Alzheimer Dis Assoc Disord Jönhagen 14 1 31 2000 10.1097/00002093-200000001-00006 Nerve growth factor treatment in dementia
Drugs Today (Barc) Allegri 48 25 2012 10.1358/dot.2012.48(Suppl.A).1739721 Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia
Biogerontology Lahiri 9 6 375 2008 10.1007/s10522-008-9162-6 Early-life events may trigger biochemical pathways for Alzheimer's disease: the “LEARn” model
J Nutr Health Aging Nelson 13 10 899 2009 10.1007/s12603-009-0249-9 Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health, and aging study
Nature Nikolaev 457 7232 981 2009 10.1038/nature07767 APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Neuropharmacology Ross 53 5 638 2007 10.1016/j.neuropharm.2007.07.015 A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat
Prog Neuropsychopharmacol Biol Psychiatry Cavas 30 1 56 2006 10.1016/j.pnpbp.2005.06.013 Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat
Nat Cell Biol Jaffrey 3 2 193 2001 10.1038/35055104 Protein S-nitrosylation: a physiological signal for neuronal nitric oxide
Hum Vaccin Coban 4 6 453 2008 10.4161/hv.4.6.6200 Molecular and cellular mechanisms of DNA vaccines
Curr Med Chem Bajda 18 32 4949 2011 10.2174/092986711797535245 Multi-target-directed ligands in Alzheimer's disease treatment
FASEB J Yogev-Falach 20 12 2177 2006 10.1096/fj.05-4910fje A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.